Moderna COVID-19 Vaccine Protects Against New COVID Variants

Moderna announced on January 25 plans for testing two different booster vaccines aimed at the SARS-CoV-2 variant B.1.351 that emerged in South Africa and has now spread to numerous countries.

Moderna COVID-19 Vaccine produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and Republic of South Africa, respectively. The study showed no significant impact on neutralizing titers against the B.1.1.7 variant relative to prior variants. A six-fold reduction in neutralizing titers was observed with the B.1.351 variant relative to prior variants. Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective.

The Moderna’s vaccine is currently administered as two doses spaced a month apart. In addition, leveraging the flexibility of the mRNA platform, Moderna is developing a booster shot for emerging variant first identified in the Republic of South Africa.

Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.

"*" indicates required fields

NAME:*

EMAIL:*

PHONE NUMBER:

COMMENTS:*

CAPTCHA

Email

This field is for validation purposes and should be left unchanged.